Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
Center for Molecular Medicine and Immunology Immunomedics, Inc.
A A A A A A A A A A A C A A A A A A A A C
A61P A61K A61P A61P A61P A61P A61P A61P A61P A61P A61P C07K A61P A61P A61P A61P A61P A61P A61P A61P C07K
inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
David M. Alice P. Chien Hsing
Goldenberg Taylor Chang